Alnylam Pharmaceuticals, Inc. insider trading
ALNYfinancial statementsForm 4 filings on EDGAR738 transactions since Nov 1, 2024
From August 4, 2026 to November 1, 2026, 0 insiders at Alnylam Pharmaceuticals, Inc. bought $0 of stock in the open market, and 1 sold $399K. Officers and directors accounted for $0 of purchases and $399K of sales. The last reported transaction was an open-market sale by Supran Bryan on October 2, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through October 6, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $399KAug 4, 2026 – Nov 1, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Oct 30, 2026. Insider data through Nov 1, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
738 transactions from November 1, 2024 to November 1, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 | Supran Bryan | EVP, CLO and Secretary | open-market sale | 1,758 | $226.88 | $399K | 12,807 | Oct 6, 2026 |
| Sep 19, 2026 | Greenstreet Yvonne | Chief Executive Officer, Director | award | 107 | $0.00 | — | 95,802 | Sep 22, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | option exercise | 3,830 | $0.00 | — | 5,412 | Jun 3, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | open-market sale10b5-1 | 921 | $297.71 | $274K | 4,491 | Jun 3, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | open-market sale10b5-1 | 1,175 | $298.91 | $351K | 3,316 | Jun 3, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | open-market sale10b5-1 | 1,222 | $299.87 | $366K | 2,094 | Jun 3, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | open-market sale10b5-1 | 495 | $300.72 | $149K | 1,599 | Jun 3, 2026 |
| Jun 1, 2026 | Pyott David E I | Director | open-market sale10b5-1 | 17 | $302.65 | $5K | 1,582 | Jun 3, 2026 |
| May 20, 2026 | Sigal Charles Elliott | Director | award | 671 | $0.00 | — | 1,446 | May 22, 2026 |
| May 20, 2026 | Schulman Amy W | Director | award | 838 | $0.00 | — | 24,049 | May 22, 2026 |
| May 20, 2026 | Reitan Colleen F | Director | award | 671 | $0.00 | — | 1,446 | May 22, 2026 |
| May 20, 2026 | Pyott David E I | Director | award | 671 | $0.00 | — | 1,582 | May 22, 2026 |
| May 20, 2026 | Kellogg Peter N | Director | award | 671 | $0.00 | — | 1,446 | May 22, 2026 |
| May 20, 2026 | Hamburg Margaret A | Director | award | 671 | $0.00 | — | 1,582 | May 22, 2026 |
| May 20, 2026 | Brandicourt Olivier | Director | award | 671 | $0.00 | — | 1,446 | May 22, 2026 |
| May 20, 2026 | Ausiello Dennis A | Director | award | 671 | $0.00 | — | 1,582 | May 22, 2026 |
| May 20, 2026 | Arbuckle Stuart A | Director | award | 671 | $0.00 | — | 671 | May 22, 2026 |
| May 13, 2026 | Schulman Amy W | Director | option exercise | 11,250 | $70.20 | $790K | 23,211 | May 14, 2026 |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 56 | $320.14 | $18K | 11,673 | Apr 7, 2026 |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 909 | $329.76 | $300K | 10,764 | Apr 7, 2026 |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 829 | $330.46 | $274K | 9,935 | Apr 7, 2026 |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 293 | $331.89 | $97K | 9,642 | Apr 7, 2026 |
| Apr 6, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 199 | $333.94 | $66K | 9,443 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 265 | $316.61 | $84K | 13,088 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 359 | $317.44 | $114K | 12,729 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 209 | $318.47 | $67K | 12,520 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 86 | $319.69 | $27K | 12,434 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 147 | $320.62 | $47K | 12,287 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 224 | $321.64 | $72K | 12,063 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 245 | $322.86 | $79K | 11,818 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 81 | $323.64 | $26K | 11,737 | Apr 7, 2026 |
| Apr 2, 2026 | McLaughlin Melissa | Chief Human Resources Officer | open-market sale10b5-1 | 8 | $325.49 | $3K | 11,729 | Apr 7, 2026 |
| Mar 5, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 500 | $326.08 | $163K | 18,693 | Mar 6, 2026 |
| Mar 5, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 510 | $324.59 | $166K | 19,193 | Mar 6, 2026 |
| Mar 5, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 740 | $323.55 | $239K | 19,703 | Mar 6, 2026 |
| Mar 5, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 654 | $322.33 | $211K | 20,443 | Mar 6, 2026 |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | open-market sale10b5-1 | 124 | $321.81 | $40K | 21,103 | Mar 6, 2026 |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | open-market sale10b5-1 | 233 | $323.25 | $75K | 20,870 | Mar 6, 2026 |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | open-market sale10b5-1 | 148 | $324.60 | $48K | 20,722 | Mar 6, 2026 |
| Mar 5, 2026 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | open-market sale10b5-1 | 153 | $326.24 | $50K | 20,569 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 106 | $319.03 | $34K | 23,300 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 102 | $320.01 | $33K | 23,198 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 208 | $325.67 | $68K | 21,097 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 272 | $324.88 | $88K | 21,305 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 767 | $323.84 | $248K | 21,577 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 350 | $323.01 | $113K | 22,344 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 289 | $321.82 | $93K | 22,694 | Mar 6, 2026 |
| Mar 4, 2026 | Garg Pushkal | EVP Chief R&D | open-market sale10b5-1 | 215 | $320.81 | $69K | 22,983 | Mar 6, 2026 |
| Mar 4, 2026 | Greenstreet Yvonne | Chief Executive Officer, Director | open-market sale | 973 | $323.84 | $315K | 96,305 | Mar 6, 2026 |
| Mar 4, 2026 | Greenstreet Yvonne | Chief Executive Officer, Director | open-market sale | 444 | $323.01 | $143K | 97,278 | Mar 6, 2026 |
Who the insiders are
Everyone who reported a transaction since November 1, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer, Director | Sep 19, 2026 | award | 95,802 | — | $20M (60) | 20 of 60 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Mar 5, 2026 | open-market sale | 21,103 | — | $10M (66) | 66 of 66 |
| Garg Pushkal | EVP Chief R&D | Mar 5, 2026 | open-market sale | 18,693 | — | $5M (53) | 31 of 53 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer | Mar 4, 2026 | open-market sale | 64,159 | — | $3M (40) | 0 of 40 |
| Tanguler Tolga | EVP, Chief Commercial Officer | Mar 4, 2026 | open-market sale | 35,894 | — | $2M (40) | 0 of 40 |
| McLaughlin Melissa | Chief Human Resources Officer | Apr 6, 2026 | open-market sale | 11,673 | — | $1M (14) | 14 of 14 |
| Pyott David E I | Director | Jun 1, 2026 | option exercise | 5,412 | — | $1M (5) | 5 of 5 |
| Supran Bryan | EVP, CLO and Secretary | Oct 2, 2026 | open-market sale | 12,807 | — | $399K (1) | 0 of 1 |
| Reitan Colleen F | Director | May 20, 2026 | award | 1,446 | — | — | — |
| Ausiello Dennis A | Director | May 20, 2026 | award | 1,582 | — | — | — |
| Bonney Michael W | Director | Aug 18, 2025 | open-market sale | 16,804 | — | — | — |
| Schulman Amy W | Director | May 20, 2026 | award | 24,049 | — | — | — |
| Sigal Charles Elliott | Director | May 20, 2026 | award | 1,446 | — | — | — |
| Kellogg Peter N | Director | May 20, 2026 | award | 1,446 | — | — | — |
| Hamburg Margaret A | Director | May 20, 2026 | award | 1,582 | — | — | — |
| Brandicourt Olivier | Director | May 20, 2026 | award | 1,446 | — | — | — |
| Sharp Phillip A | Director | Jan 23, 2025 | open-market sale | 0 | — | — | — |
| Arbuckle Stuart A | Director | May 20, 2026 | award | 671 | — | — | — |
| Bertozzi Carolyn R | Director | May 8, 2025 | award | 775 | — | — | — |
| Hesslein Robert W. | EVP, CLO and Secretary | Mar 3, 2025 | award | 8,002 | — | — | — |
Questions
Are Alnylam Pharmaceuticals, Inc. insiders buying or selling?
Over the twelve months to November 1, 2026, 8 insiders at Alnylam Pharmaceuticals, Inc. sold $44M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $44M. Only open-market purchases and sales are counted.
Who sold the most Alnylam Pharmaceuticals, Inc. stock in the last year?
Greenstreet Yvonne (Chief Executive Officer, Director) sold $20M in 60 open-market sales over the twelve months to November 1, 2026.
Do Alnylam Pharmaceuticals, Inc. executives sell under 10b5-1 plans?
136 of the 279 open-market sales in the last twelve months (49%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.